Exelixis, Inc.
EXELNext catalyst
Zanzalintinib
patients with metastatic CRC who have been previously treated with fluoropyrimidine-
Get an email about EXEL's next catalysts
Track Exelixis (EXEL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 13 more upcoming events in our data (Phase 2 readout, Phase 3 readout, PDUFA date).See the timeline
14 upcoming, 1 past
Cabozantinib Phase 2 Est. Readout (CANOPY)
Estimated primary completion for Cabozantinib trial (NCT05502315) in Castration-resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date zanzalintinib
For patients with metastatic CRC who have been previously treated with fluoropyrimidine-. nda filing. Extracted from SEC filing: EX-99.1
SourceXL092 Phase 3 Est. Readout (STELLAR-304)
Estimated primary completion for XL092 trial (NCT05678673) in Non-Clear Cell Renal Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceCabozantinib Phase 2 Est. Readout
Estimated primary completion for Cabozantinib trial (NCT05263050) in Metastatic Renal Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceCabozantinib Phase 2 Est. Readout
Estimated primary completion for Cabozantinib trial (NCT04413123) in Papillary Renal Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceZanzalintinib Phase 2 Est. Readout (ZENOBIA)
Estimated primary completion for Zanzalintinib trial (NCT06698250) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceCabozantinib Phase 2 Est. Readout
Estimated primary completion for Cabozantinib trial (NCT04472767) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceCabozantinib Phase 2 Est. Readout
Estimated primary completion for Cabozantinib trial (NCT04551430) in Metastatic Soft-tissue Sarcoma. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
WebsitePembrolizumab (+) Berahyaluronidase alfa
Colorectal Cancer
XL184
Glioblastoma Multiforme
Regorafenib
Colorectal Cancer
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
Cabozantinib tablets
Renal Cell Carcinoma
Cabozantinib
Solid Tumors
XL092
Non-Clear Cell Renal Cell Carcinoma
XL820
Gastrointestinal Stromal Tumors
Cabozantinib (XL184)
Relapsed or Refractory Multiple Myeloma
Etoposide Capsule
Germ Cell Tumor
Cabozantinib S-malate
Poorly Differentiated Thyroid Gland Carcinoma
Androgen Ablation Therapy
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab (+) Berahyaluronidase alfa | Phase 3 | Colorectal Cancer | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
Cabozantinib | Phase 3 | Solid Tumors | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Cabozantinib (XL184) | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Etoposide Capsule | Phase 2 | Germ Cell Tumor | - | - |
Cabozantinib S-malate | Phase 2 | Poorly Differentiated Thyroid Gland Carcinoma | - | - |
Androgen Ablation Therapy | Phase 2 | Prostate Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Exelixis, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Exelixis, Inc.'s (EXEL) pipeline across Phase 3, Phase 2. Its lead program is Zanzalintinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Exelixis, Inc.'s next FDA catalyst?→
Exelixis, Inc.'s (EXEL) next tracked catalyst is a PDUFA date expected Dec 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EXEL biotech catalysts?→
Add EXEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Exelixis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.